On the FDA’s docket for the back half of September is Merck’s proposed subcutaneous formulation of its blockbuster cancer ...

In a landmark regulatory achievement that reflects the UAE’s leadership in accelerating access to innovative therapies, the Emirates Drug Establishment has announced the approval of “Tolebrutinib” as ...

Sanofi to present new data from 14 abstracts across multiple sclerosis at ECTRIMS 2025 congress in Barcelona, Spain ...

Some of Sanofi’s most high-profile readouts this year can’t have made for easy reading at the French pharma’s Paris ...

In a landmark regulatory achievement that reflects the UAE’s leadership in accelerating access to innovative therapies, the Emirates Drug Establishment has announced the approval of “Tolebrutinib” as ...

Abu Dhabi [UAE], August 26 (ANI/WAM): In a landmark regulatory achievement that reflects the UAE's leadership in accelerating access to innovative therapies, the Emirates Drug Establishment has ...

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is ...

Specialty and orphan drugs continue to dominate the development pipeline, and a new report from Optum Rx spotlights three products payers should be watching. | Specialty and orphan drugs continue to ...

Sanofi ( NASDAQ: SNY) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT ...

Secondary progressive multiple sclerosis (SPMS) can be active or inactive. Learn about the differences and how it impacts treatment.